Home/Theratome Bio/Michael T. Redman

MT

Michael T. Redman

Chief Executive Officer

Therapeutic Areas

Ophthalmology Transplant Medicine Regenerative Medicine

Theratome Bio Pipeline

Drug	Indication	Phase
Organ Preservation Product	Organ Transplant Preservation (e.g., Heart)	Pre-clinical
KM102	Dry Eye Disease	Pre-clinical

Leadership Team at Theratome Bio

Keith L. March, MD, PhD, FACC

Scientific Founder, Board Member

Michael Coleman

Chief Scientific Officer

Chief Financial Officer

View full Theratome Bio profile